Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Palmitoyl-dipeptide-6

Palmitoyl Dipeptide-6 Diaminohydroxybutyrate, Pal-Lys-Val-Dab

Quick Stats
Studies 98
Trials 0
Score 1
2025 pubmed

Amelioration of intervertebral disc degeneration using engineered extracellular vesicle-delivered ZDHHC5 via inhibiting PANoptosis.

Chen. Tong T; Zhang. Helong H; Lv. Songtao S; Xu. Yue Y; Ren. Wei W; Wei. Yifan Y; Zhang. Tianyou T; Ge. Yunru Y; Lv. You Y; Li. Ruya R; Che. Hui H; Xie. Kunxin K; Ren. Yongxin Y; Ma. Cheng C

Key Findings

  • PANoptosis is a key driver of intervertebral disc degeneration.
  • Parathyroid hormone (PTH) boosts the amount and changes the cargo of stem‑cell‑derived extracellular vesicles (EVs).
  • PTH‑preconditioned EVs deliver ZDHHC5, which palmitoylates YBX1, reducing ZBP1 transcription and thus inhibiting PANoptosis.

Practical Outcomes

  • For most biohackers, the work suggests that targeting PANoptosis might be useful for spinal health, but it does not provide a clear, actionable protocol or dosage for using palmitoyl‑dipeptide‑6. Until the peptide’s role is directly tested, the findings remain mainly of academic interest.

Summary

Scientists found that tiny particles released by stem cells, when pre‑treated with a hormone, can protect spinal discs from a type of cell death called PANoptosis. They think this works because the particles carry a protein (ZDHHC5) that adds a fatty tag (palmitoylation) to another protein, stopping a harmful chain reaction. The study does not test the peptide palmitoyl‑dipeptide‑6 itself, so it offers little direct guidance for DIY biohackers.

Abstract

Intervertebral disc degeneration (IDD) is a common condition and a leading cause of chronic low back pain, affecting millions of individuals worldwide. Human Umbilical Cord Mesenchymal Stromal Cell (hUCMSC)-derived extracellular vesicles (EVs) are emerging as a promising therapeutic strategy for IDD. However, the limited production yield and unclear mechanisms by which EV contents mediate their therapeutic effects have hindered the clinical application of EVs. In this study, using transcriptomic data and single-cell RNA sequencing, we identify PANoptosis as a key mechanism driving the progression of IDD. Furthermore, parathyroid hormone (PTH) enhances the secretion of hUCMSC-derived EVs and alters their cargo composition, which may contribute to their improved therapeutic effects. Mechanistically, PTH-preconditioned EVs, enriched with ZDHHC5, ameliorate PANoptosis by modulating ZBP1 transcription through competitive inhibition of YBX1 phosphorylation via palmitoylation. Our findings provide strong support for a cell-free therapeutic strategy utilizing EVs from PTH-preconditioned MSCs for IDD treatment and propose the ZDHHC5/YBX1/ZBP1 axis as a novel molecular target for inhibiting PANoptosis, thus paving the way for clinical translation and broader healthcare applications.

Study Information

Provider

pubmed

Year

2025

Date

2025-10-27T00:00:00.000Z

DOI

10.1177/20417314251351011

References

63